05 February 2017

Reproductive genetics to enable higher success rates and prevent transmission of genetic disorders: Igenomix

As a pioneer in reproductive genetics, Igenomix has continuously invested in research and development to bring out new and effective techniques which ...

RECENT ARTICLES

As a pioneer in reproductive genetics, Igenomix has continuously invested in research and development to bring out new and effective techniques which today contribute significantly to the Assisted Reproduction Techniques industry.

Igenomix is helping most of the clinicians in the Middle East to increase the pregnancy rate by 24% with the use of ERA (Endometrial Receptivity Analysis). This study was presented by Professor Simón, scientific director of Igenomix at the 72nd AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE Scientific Congress (ASRM) and has been awarded as Prize Paper by the Society for Reproductive Endocrinology and Infertility (SREI) in October last year. The ERA test personalizes treatment and works out the day in which the embryo transfer will be successful for 85% of patients.

Igenomix can support the families and clinicians to reduce the risk of having an affected child with a genetic disorder. Carrier Genetic Test (CGT) by Igenomix is another state of the art screening technique that analyse more than 600 diseases to identify the risk of transmission of genetic disorder to the child before conception. 90% of cases analyzed by Igenomix so far are carriers of at least one mutation which poses a great risk for the child. The risks of genetic disorders are greater for children born to consanguineous couples. In a recent study, 19.7% of the consanguineous couples were at a high risk of passing on the genetic disorder to their child.  PGD (Preimplantation Genetic Diagnosis) can be employed in cases where both parents are carriers of same genetic disorder to help them conceive a healthy baby through IVF.

Chromosomal abnormalities such as Down’s syndrome are extremely common especially in older pregnancies. NACE is a non invasive prenatal test that screens the baby for common chromosomal abnormalities without any threat to mother or child as it maybe in case of invasive techniques such as amniocentesis. The test also reveals the baby’s gender and fetal fraction data for ease of diagnosis for gynecologists and other concerned specialists.

With over two decades of experience in reproductive genetics, IGENOMIX is one of the global leaders with presence in 50 countries. They have also been awarded accreditation by College of American Pathologist (CAP) for its quality standards and are the first private genetic lab in Dubai to receive it.

Further information about the company at https://www.igenomix.ae

Topics: Igenomix AE, top-news

Other recommended articles

11 July 2018

IGENOMIX DEVELOPS THE FIRST MOLECULAR DIAGNOSTIC TOOL FOR CHRONIC ENDOMETRI...

06 July 2018

A study by Igenomix opens the door for non-invasive analysis of the embryo

24 May 2017

Igenomix Dubai Wins 2017 Frost and Sullivan’s Specialized Genetic Diagnosti...

07 May 2017

Igenomix’s Carrier Genetic Test Can Save Children From Inheriting Genetic D...

Do you want to start using our Genetic Services?

For further assistance please contact our customer support team by phone or e-mail

Contact us

Igenomix is in the media

Igenomix is not affiliated with any news outlet or publication identified above. News coverage does not constitute an endorsement of Igenomix or its products.

Newsletter subscription